Artios Pharma
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
B940 Babraham Research Campus, Cambridge...Phone Number
+44 1223867900Website
www.artios.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Artios Pharma
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers. The companys clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Pol) inhibitor ART6043, as well as its pre-clinical programs, including DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cells remaining survival mechanisms. Artios mission is to develop new classes of medicines that exploit DDR pathways with the aim of improving outcomes for patients with hard-to-treat cancers.Explore more
Artios Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Artios Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Artios Pharma has new funding data
Artios Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Artios Pharma recently announced quarterly report
Product Launch: Get notified when Artios Pharma launches new products
Click to see if Artios Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Artios Pharma
Check if Artios Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Artios Pharma is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Artios Pharma
Compare insights from companies similar to Artios Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Artios Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Artios Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Artios Pharma.
Artios Pharma financials insights
Gather financial insights about Artios Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$33.2M
2018
Series B
$84M
2021
Series C
$153M
2025
Series D
$115M
Artios Pharma Tech Stack
A closer look at the technologies used by Artios Pharma
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Artios Pharma News & Media
Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors
CAMBRIDGE, United Kingdom and NEW YORK, May 12, 2026 – Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today announced a clinical trial collaboration and supply agreement with GSK to evaluate alnodesertib, Artios’ ATR inhibitor, in combination with risvutatug rezetecan (also referred to as Ris-Rez), GSK’s novel investigatiArtios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution
CAMBRIDGE, United Kingdom and NEW YORK, May 04, 2026 – Artios Pharma Limited (“Artios” or “the Company”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today announced the appointment of three senior executives to the leadership team as the Company accelerates its potential first-in-class oncology pipeline. Jeremy B. Fitch, MBA, joins as Chief Business OArtios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with HGSOCArtios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Artios Pharma
Sign Up For FreeTo access detailed company insights
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers. The companys clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Pol) inhibitor ART6043, as well as its pre-clinical programs, i... Read More
